With a mission to support novel approaches to managing and preventing heart failure, the Ted Rogers Centre for Heart Research uses its Innovation Fund to propel emerging research with great potential. The 2024-25 Innovation Fund Seed Grants are currently open and you...
The Ted Rogers Centre for Heart Research is delighted to welcome Iris Cohn as the new Innovator in Genomic Translation - also recently promoted to Director of the Pharmacogenetics (PGx) Program at The Hospital for Sick Children. A trained pharmacist, Iris established...
NorthMiRs Inc., an innovative cardiovascular biotech start-up, has won $250,000 in funding from the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) PITCH 2024 competition. Since its launch in 2018, the ECHO...
Congenital heart disease (CHD) is the most commonly occurring birth anomaly. Despite a strong genetic basis, almost 90% of cases remain genetically undiagnosed. However, the surge of new technology is enabling a search for hidden gene defects not detectable on...
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
This Right Ventricle focused meeting is unique in spanning basic, translational and clinical topics to address contemporary research and clinical questions from bench to bedside. Distinguished international faculty of experts will discuss unique aspects of RV biology, physiology and failure, how to image the RV, medical and surgical solutions to RV disease, and future directions in RV research.
Course Objectives:
1. Gain a comprehensive understanding of RV physiology, its adaptation to adverse loading and failure in congenital and acquired heart disease.
2. Understand the diagnosis and management of RV dysfunction and its interaction with the left ventricle and pulmonary vasculature.
3. Update on the most current bench and bedside research as a basis for future diagnosis and therapies.